End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19,640 KRW | +1.92% |
|
+2.13% | -6.48% |
Jun. 12 | Lotte Card Teams Up With Macrogen for Genetic Testing Services | MT |
2023 | Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022. | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.48% | 143M | - | ||
+22.10% | 46.55B | B- | ||
+46.45% | 41.84B | A | ||
-3.12% | 40.84B | B | ||
+36.10% | 32.95B | B | ||
-6.30% | 28.27B | C | ||
+18.71% | 27.78B | B- | ||
+46.15% | 14.26B | B+ | ||
+44.52% | 13.69B | C+ | ||
+0.19% | 12.18B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A038290 Stock
- Ratings Macrogen, Inc.